All In MedTech

Device Trial Radar · NCT05574777

Endoscopic Gastric Mucosal Ablation (GMA) of Class III Obesity

Safety and Feasibility of HybridAPC for Gastric Mucosal Ablation in the Management of Patients With Class III Obesity

Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

13

Actual

Start

Apr 13, 2023

Primary completion

Aug 22, 2025

Study completion Mar 30, 2026

Sponsor

Lead sponsor
Erbe Elektromedizin GmbHNot on our public-company list
Sponsor type
Industry
Collaborators
Erbe do Brasil Chirúrgicos e Endoscópicos LTDA; Bioscience Consulting, Inc.
First posted
Oct 12, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 21 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is intended to investigate safety and feasibility of a new weight loss technique called Gastric Mucosal Ablation (GMA) that does not require surgery, but can be achieved using an endoscopic procedure. Previous studies have suggested that weight loss after vertical sleeve gastrectomy (VSG) is partly due to the removal of normal stomach tissue suspected of having hormonal function. The study will investigate the minimally invasive treatment of obesity Class III participants by means of argon plasma coagulation (APC) in combination with waterjet submucosal injection using HybridAPC. As primary endpoint device or procedure related occurrence of complications according to Clavien-Dindo classification will be determined. After signing the informed consent the doctor and research team will determine if the participant meets all requirements for this study. If a participant is confirmed to be a suitable candidate additional tests will be performed prior to the first application of GMA to assess the health status of the participant prior to treatment. During the screening and baseline visit the medical history and the medications of the participant will be reviewed. After the treatments the participants will be followed for up to 6 months to assess the outcome of the GMA procedure.

Conditions

  • Adiposity
  • Morbid
  • Obesity

Interventions

  • Hybrid Argonplasma coagulation (HAPC)Device

    Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation to the gastric mucosa and preventing thermal damage to the muscle layer.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of complications related to the device or procedureTime frame: 9 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

    São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.